New migraine pill promises fast pain relief in Real-World study

NCT ID NCT05903027

Recruiting now Symptom relief Sponsor: University of Florence Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing how well and how safely the drug rimegepant works for treating migraine attacks as they happen. Researchers will follow 100 people with migraine (with or without aura, or chronic migraine) who take a 75 mg rimegepant tablet when they have an attack. The main goal is to see if they are pain-free 2 hours after taking the drug, and to track any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rimegepant 75 mg orally disintegrating tablet
What this could lead to: If successful, this could confirm rimegepant as a reliable option for quickly stopping migraine pain in both episodic and chronic migraine patients.
What could go wrong: This is an observational study with only 100 participants, so results may not apply to everyone. Rimegepant may cause side effects or not work for all types of migraine.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MIGRAINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Headache Headache Disorders, Secondary migraine disorder migraine with aura migraine without aura Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC MIGRAINE MIGRAINE MIGRAINE WITH AURA MIGRAINE WITHOUT AURA

Contacts and locations

Locations

IRCCS National Neurological Institute "C. Mondino" Foundation
RECRUITING

Pavia, 27100, Italy
SOD Centro Cefalee e Farmacologia Clinica, AOU Careggi
RECRUITING

Florence, 50134, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.